Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine
US11518743B2 · kind B2 · utility
3Cited by
4References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 27, 2022 |
| Grant date | Dec 6, 2022 |
| Priority date | — |
| Expiry date | Apr 27, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.